Holding 3 clinical approval documents in hand, participating in the formulation of US Pharmacopoeia industry standards... Triassic opens a new era of 3D printing drugs

At present, Tridecium has 127 international patent applications, accounting for more than 20% of the global 3D printing drug field.
It is the company with the most complete patent layout and the largest number of applications in this field
.
There are a total of 4 3D printed pharmaceutical products that have entered or completed the registration application worldwide, and Triassic contributed 3 of them

On October 27th, the global leader in the field of 3D printing drugs, Nanjing Sandieji Pharmaceutical Technology Co.
, Ltd.
(abbreviated as Sandieji) disclosed its corporate development path and 2.
0 era opening strategy: through opening up technical resources, establishing a relationship with global pharmaceutical companies To realize the commercialization of 3D printing drug technology
.

Dr.
Mori Ping Cheng, founder and CEO of Triassic, said: “The six-year Triassic of innovation and entrepreneurship has already accumulated energy to go far
.
While continuing to carry out technological innovation, Triassic will use the power of platform technology to serve Global pharmaceutical companies promote the digitalization and intelligence of the preparation industry

The birth of Triassic originated from "a scientific imaginary, a dream to change the world"

From 2015 to 2019, in the era of Triassic 1.
0, with intellectual property-driven strategy, the development of 3D printing drug platform technology was completed
.
From 2020 to 2025, in the era of Triassic 2.

At present, Triassic has 127 international patent applications, accounting for more than 20% of the global 3D printing drug field.
It is the company with the most complete patent layout and the largest number of applications in this field
.
There are a total of four 3D printed pharmaceutical products that have entered or completed the registration application worldwide, and Triassic contributed three of them

Technological innovation is the engine of sustained growth in the pharmaceutical industry
.
Triassic’s MED®3D printing drug production technology has revolutionized the traditional pharmaceutical process and redefines the underlying logic, process flow and production mode of the formulation technology based on Industry 4.

Dr.
Cheng Moriping said: “At present, Triassic’s 3D printing drug equipment has been iterated more than ten times and has ten product pipelines
.
By the end of this year, Triassic will build a continuous production line for 3D printed drugs with an annual capacity of 50 million tablets

According to the company's disclosure, T19, Sandieji's first 3D printed drug product, was approved by the US FDA in January 2021 for the treatment of rheumatoid arthritis.